We started ApexLens because we believed retail investors deserved the same quality of research that institutional money managers use — without the conflicts, jargon, or six-figure price tags.
Wall Street research has always been primarily a product sold to hedge funds, asset managers, and large institutions — retail investors get the filtered-down version, often months later, often with the juiciest insights stripped out.
ApexLens was founded in 2018 with a simple thesis: high-quality, independent stock research, published transparently, with no brokerage relationships, no investment banking mandates, and no hidden incentives.
We write for the individual investor who has a full-time job, a meaningful portfolio, and wants to make informed decisions with their own capital — not blindly follow consensus.
We accept no payment from companies we cover, no soft-dollar arrangements, and no sponsored research. Our only incentive is to be right.
Every pick comes with a clearly articulated thesis, explicit risk factors, a time horizon, and a target price — not vague directional commentary.
We publish every rating change, every missed call, and every update. Our performance history is available in full — no cherry-picking.
We write for intelligent people who haven't spent 20 years on a trading desk. No unnecessary jargon; complexity explained, not weaponized.
We focus on business fundamentals over a 1–3 year horizon — not next quarter's earnings whisper. We're investors, not traders.
Our educational content, market outlook, and a meaningful subset of picks are always free. We believe financial literacy is a public good.
Former equity research analyst at a bulge-bracket firm covering technology. 14 years of institutional experience. CFA charterholder.
Background in biotech and medtech equity research. Previously at a long/short healthcare-focused fund. MS in Biochemistry, MBA from Wharton.
Spent 10 years in buy-side research before joining ApexLens. Specialist in value investing and interest rate macro analysis. CFA charterholder.
Former CPA specializing in individual investment tax strategy. Translates complex tax research into actionable guidance for retail investors.
Weekly stock picks, macro commentary, and investor education — free, every Sunday.